BioWorld

March 19, 2002

View Archived Issues

Biovail Pays Solvay $94M For Hypertension Treatment

Read More

Armed T Cells Take On Mission Ambushing Tumor Cells, Guiding Killer Genes Into Lethal Position

Read More

AlgoRx Gets $25M In Series B, Buys PowderJect Technology

Read More

U.S. Patent Disclosures

Read More

Other News To Note

Read More

ViroPharma’s Picovir Goes Before FDA Panel; Analysts Divided

WASHINGTON In recent days, ViroPharma Inc. has been the subject of speculation surrounding the outcome of today’s government panel hearing on whether to recommend Picovir as a treatment for the common cold. (BioWorld Today) Read More